Conversely, patients with severe calciphylaxis or extensive osteitis fibrosa cystica may favor TPTX to ensure definitive PTH reduction, despite the risk of transient hypocalcemia [30,31]. The gene discussed is PTH; the disease is osteitis fibrosa.